BPN14770 Improved Men’s Language, Daily Functions

BPN14770 Improved Men’s Language, Daily Functions

293529

BPN14770 Improved Men’s Language, Daily Functions

Tetra Therapeutics’ investigational oral therapy BPN14770 safely and effectively improves cognitive function, particularly language-related domains, and daily functioning in men with fragile X syndrome, according to data from a Phase 2 clinical trial. “These results offer hope for patients with fragile X syndrome and their families,” Elizabeth Berry-Kravis, MD, PhD, said in a press release. Berry-Kravis is the trial’s principal investigator and a pediatric neurologist at Rush University Medical Center in Chicago, Illinois. Most clinical outcome…

You must be logged in to read/download the full post.